Categories: विदेश

BRIEF-JCR Pharmaceuticals Announces Licensing Agreement With Menagen To Commercialize Agalsidase Beta BS I.V. Infusion

Oct 1 (Reuters) – JCR Pharmaceuticals Co Ltd: * JCR PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH MENAGEN TO COMMERCIALIZE AGALSIDASE BETA BS I.V. INFUSION ACROSS NINE MENAT MARKETS * JCR PHARMACEUTICALS CO LTD: DOES NOT EXPECT A MATERIAL IMPACT ON FY2025 CONSOLIDATED RESULTS FROM MENAGEN DEAL Source text: Further company coverage: ;))

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Inkhabar webdesk

Share
Published by Inkhabar webdesk

Recent Posts

K-Pop sensation BTS to return with new album on March 20

SEOUL, Jan 1 (Reuters) - K-Pop sensation BTS will return with a new album on…

4 hours ago

K-Pop sensation BTS to return with new album on March 20

SEOUL, Jan 1 (Reuters) - K-Pop sensation BTS will return with a new album on…

14 hours ago

K-Pop sensation BTS to return with new album on March 20

SEOUL, Jan 1 (Reuters) - K-Pop sensation BTS will return with a new album on…

15 hours ago

"Zootopia 2" breaks record to become top-grossing Disney animation film

Dec 31 (Reuters) - Walt Disney Animation Studios' "Zootopia 2" surpassed 2019's "Frozen 2" to…

17 hours ago

Netflix Christmas Day NFL streams set US viewership records

Dec 31 (Reuters) - Netflix's Christmas Day National Football League broadcasts set new records, with…

18 hours ago

Netflix Christmas Day NFL streams set US viewership records

Dec 31 (Reuters) - Netflix's Christmas Day National Football League broadcasts set new records, with…

18 hours ago